CCO Independent Conference Highlights of the IASLC 2022 World Conference on Lung Cancer*

Download All
August 6-9, 2022; Vienna, Austria
Download capsule summaries highlighting key studies from IASLC 2022 WCLC and then read expert insights on these studies in our Expert Analysis text module.
Wade T. Iams, MD, MSCI
Heather Wakelee, MD, FASCO

WCLC Highlights

Slidesets TROPION-Lung02: Initial Results From Phase I Study of Datopotamab Deruxtecan + Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
Slidesets Population-Based Assessment of Socioeconomic Treatment Inequities With Biomarker-Guided Targeted Therapy and Immunotherapy for Patients With NSCLC
Slidesets CodeBreaK101: Phase Ib/II Study With Sotorasib + RMC-4630, an SHP2 Inhibitor, in Advanced NSCLC and Other Solid Tumors With KRAS p.G12C Mutation
Slidesets CodeBreaK100/101: Phase Ib Report of Safety and Efficacy of Sotorasib + Atezolizumab or Pembrolizumab in Patients With Pretreated KRAS G12C–Mutated NSCLC
Slidesets DeLLphi-300: Updated Data From Phase I Study of Tarlatamab, a DLL3-Targeted T-Cell Engager, in Relapsed/Refractory SCLC
Slidesets HUDSON: Open-Label, Multidrug Umbrella Phase II Study in Patients With Advanced NSCLC After Progression on PD-1/PD-L1 Inhibitor Therapy
Slidesets Results of a Pooled Outcomes Analysis of Phase III Trials Using a Second Course of Pembrolizumab in Advanced NSCLC
Slidesets YESS: Effectiveness of Adding Colocated Personalized Smoking Cessation Support to a Lung Cancer Screening Program
Slidesets CALGB 140503 (Alliance): Phase III Trial of Lobar or Sublobar Resection for Peripheral Clinical Stage IA NSCLC With Tumor Size ≤2 cm
Slidesets IMpower010: Updated Data of Phase III Trial of Adjuvant Atezolizumab vs BSC in Resected Stage IB-IIIA NSCLC After Adjuvant Chemotherapy
Slidesets NADIM II: Survival Results From Phase II Study of Nivolumab + Chemotherapy vs Chemotherapy as Neoadjuvant Treatment for Resectable IIIA-B NSCLC

Read about key studies highlighted by experts being presented at the upcoming IASLC 2022 WCLC annual meeting. The CCO WCLC Conference Coverage program will have the information you need to understand and integrate the latest oncology data into your clinical practice.

Wade T. Iams, MD, MSCI Heather Wakelee, MD, FASCO Released: August 5, 2022

Review expert perspectives on the most clinically relevant data on lung cancers presented at the 2022 IASLC World Conference on Lung Cancer.

Wade T. Iams, MD, MSCI Heather Wakelee, MD, FASCO Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: October 25, 2022 Expired: October 24, 2023
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.
Turning Point Therapeutics, Inc.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings